{"id":390030,"date":"2021-05-06T00:00:00","date_gmt":"2021-05-06T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0017-2021-biopharma-acute-myeloid-leukemia-current-treatment-physician-insights-us-2021\/"},"modified":"2026-03-31T10:43:22","modified_gmt":"2026-03-31T10:43:22","slug":"cutron0017-2021-biopharma-acute-myeloid-leukemia-current-treatment-physician-insights-us-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0017-2021-biopharma-acute-myeloid-leukemia-current-treatment-physician-insights-us-2021\/","title":{"rendered":"Acute Myeloid Leukemia | Current Treatment: Physician Insights | US | 2021"},"content":{"rendered":"<p>Acute myeloid leukemia (AML), the most common form of leukemia in adults, is associated with poor five-year overall survival rates. After years of chemotherapy-dominated treatment, the FDA approved four drugs for AML in 2017 (Pfizer\u2019s Mylotarg, Novartis\u2019s Rydapt, Agios\u2019s Idhifa, and Jazz\u2019s Vyxeos) and four more drugs in 2018 (Agios\u2019s Tibsovo, AbbVie \/ Roche\u2019s Venclexta, Pfizer\u2019s Daurismo, and Astellas\u2019s Xospata). The most recent addition to the treatment armamentarium is Bristol Myers Squibb \/ Celgene\u2019s Onureg, approved as a maintenance therapy. In light of the impressive data from many newly approved drugs for AML subpopulations, the treatment paradigm is changing rapidly as it moves toward targeted and personalized therapies.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>Following the FDA\u2019s approval of nine drugs for AML since 2017, how do physicians incorporate these additional therapies into their practice?<\/li>\n<li>What is the uptake of AbbVie \/ Roche\u2019s Venclexta in patients ineligible for intensive induction? Which Venclexta-based combinations are prescribed most frequently?<\/li>\n<li>Is Astellas\u2019s Xospata prescribed for <em>FLT3<\/em> mutation-positive patients in the relapsed\/refractory setting? How is the drug\u2019s uptake affected by other FLT3 inhibitors, including Novartis\u2019s Rydapt in the previously untreated setting and Nexavar in the relapsed\/refractory setting?<\/li>\n<li>What will be the uptake of IDH inhibitors in patients with <em>IDH<\/em> mutations?<\/li>\n<li>What are the key prescribing drivers and obstacles facing novel therapies such as Daurismo and Onureg?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Current Treatment<\/em>:<em> Physician Insights<\/em> provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Markets covered: <\/strong>United States<\/p>\n<p><strong>Primary research:<\/strong><strong> <\/strong> Survey of 101 U.S. hematologist-oncologists<\/p>\n<p><strong>Key drugs covered:<\/strong> Venclexta, Xospata, Idhifa, Tibsovo, Vyxeos, Daurismo, Mylotarg, Rydapt, Onureg<\/p>\n<p><strong>Key insights provided<\/strong><\/p>\n<ul>\n<li>Factors influencing disease management and treatment decisions.<\/li>\n<li>Drivers and constraints of treatment selection.<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390030","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-myeloid-leukemia","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390030\/revisions"}],"predecessor-version":[{"id":393155,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390030\/revisions\/393155"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}